Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,033 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study).
Ozaki A, Yoneda M, Kessoku T, Iwaki M, Kobayashi T, Honda Y, Ogawa Y, Imajo K, Sakai E, Taguri M, Yamanaka T, Iwasaki T, Kurihashi T, Saito S, Nakajima A. Ozaki A, et al. Among authors: ogawa y. Contemp Clin Trials Commun. 2019 Dec 31;17:100516. doi: 10.1016/j.conctc.2019.100516. eCollection 2020 Mar. Contemp Clin Trials Commun. 2019. PMID: 31956725 Free PMC article.
Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design.
Kessoku T, Imajo K, Kobayashi T, Honda Y, Kato T, Ogawa Y, Tomeno W, Kato S, Higurashi T, Yoneda M, Kirikoshi H, Kubota K, Taguri M, Yamanaka T, Usuda H, Wada K, Saito S, Nakajima A. Kessoku T, et al. Among authors: ogawa y. Contemp Clin Trials. 2018 Jun;69:40-47. doi: 10.1016/j.cct.2018.04.002. Epub 2018 Apr 5. Contemp Clin Trials. 2018. PMID: 29627620
Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study.
Ozaki A, Kessoku T, Iwaki M, Kobayashi T, Yoshihara T, Kato T, Honda Y, Ogawa Y, Imajo K, Higurashi T, Yoneda M, Taguri M, Yamanaka T, Ishiki H, Kobayashi N, Saito S, Ichikawa Y, Nakajima A. Ozaki A, et al. Among authors: ogawa y. Trials. 2020 Jun 1;21(1):453. doi: 10.1186/s13063-020-04385-0. Trials. 2020. PMID: 32487150 Free PMC article.
Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.
Yoneda M, Honda Y, Ogawa Y, Kessoku T, Kobayashi T, Imajo K, Ozaki A, Nogami A, Taguri M, Yamanaka T, Kirikoshi H, Iwasaki T, Kurihashi T, Saito S, Nakajima A. Yoneda M, et al. Among authors: ogawa y. BMJ Open Diabetes Res Care. 2021 Feb;9(1):e001990. doi: 10.1136/bmjdrc-2020-001990. BMJ Open Diabetes Res Care. 2021. PMID: 33593749 Free PMC article. Clinical Trial.
Endotoxins and Non-Alcoholic Fatty Liver Disease.
Kessoku T, Kobayashi T, Imajo K, Tanaka K, Yamamoto A, Takahashi K, Kasai Y, Ozaki A, Iwaki M, Nogami A, Honda Y, Ogawa Y, Kato S, Higurashi T, Hosono K, Yoneda M, Okamoto T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Kessoku T, et al. Among authors: ogawa y. Front Endocrinol (Lausanne). 2021 Oct 29;12:770986. doi: 10.3389/fendo.2021.770986. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34777261 Free PMC article. Review.
Emerging drugs for non-alcoholic steatohepatitis.
Tomeno W, Yoneda M, Imajo K, Ogawa Y, Kessoku T, Saito S, Eguchi Y, Nakajima A. Tomeno W, et al. Among authors: ogawa y. Expert Opin Emerg Drugs. 2013 Sep;18(3):279-90. doi: 10.1517/14728214.2013.811232. Epub 2013 Jul 13. Expert Opin Emerg Drugs. 2013. PMID: 23848366 Review.
5,033 results